Previous 10 | Next 10 |
On March 4, Sesen Bio's ( SESN ) President and CEO Dr. Thomas Cannell held a conference call, primarily to update the status and progress of Vicinium. A Brief Background Vicinium is being developed for non-muscle invasive bladder cancer (NMIBC), a very common cancer for which no new trea...
Sesen Bio, Inc. (NASDAQ:SESN) Q4 2018 Earnings Conference Call March 4, 2019 8:00 AM ET Company Participants Erin Clark - Executive Director, Strategic Planning & Investor Relations Thomas Cannell - President and Chief Executive Officer Dennis Kim - Chief Medical Officer ...
The following slide deck was published by Sesen Bio, Inc. in conjunction with their 2018 Q4 earnings Read more ...
Nightstar Therapeutics Plc (NASDAQ: NITE ) +66% on being acquired by Biogen. More news on: Nightstar Therapeutics plc, Ascendis Pharma, China Internet Nationwide Financial Services Inc., Stocks on the move, Read more ...
Company Announces Additional Key Primary and Secondary Endpoints Further Supporting Vicinium ® Treatment Potential in High-Risk Non-Muscle Invasive Bladder Cancer Company on Track to Report Updated 12-Month Data from Phase 3 VISTA Trial of Vicinium in Mid-2019 Management...
Sesen Bio (NASDAQ: SESN ): FY GAAP EPS of -$0.55. More news on: Sesen Bio, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of people with cancer, today announced that Company management will host a conference call and webcast on Monday, March 4, 2019 at 8:00 a.m. EST to review operating res...
Editor's note: Seeking Alpha is proud to welcome Ting Peterson as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » About Sesen...
Quick Take Anchiano Therapeutics ( ANCN ) intends to raise $35 million in a U.S. IPO, per an amended regulatory filing . The company is developing a single biologic candidate to treat bladder and other cancers. ANCN has had promising trial results, strong existing investor support of th...
HENDERSON, NV / ACCESSWIRE / January 22, 2019 / The stock market reached a level toward the end of last year where investors and analysts feared a recession. Some of this fear was over a U.S. China trade war; now that we've seen positive news on President Trump talks with President Xi, the m...
News, Short Squeeze, Breakout and More Instantly...
Sesen Bio Inc. Company Name:
SESN Stock Symbol:
NASDAQ Market:
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...